Pharming amends Ruconest distribution deal with SOBI

Netherlands-based Pharming Group (Euronext: PHARM) and rare diseases specialist Swedish Orphan Biovitrum (STO: SOBI) have amended their Ruconest distribution agreement signed in 2009. Ruconest (recombinant human C1 inhibitor) is a treatment for acute attacks of hereditary angioedema (HAE)

In addition to Austria, Germany and Netherlands, Pharming will market Ruconest directly into an additional 21 countries, effective October 1, 2016. These countries include Algeria, Andorra, Bahrain, Belgium, France, Ireland, Jordan, Kuwait, Lebanon, Luxembourg, Morocco, Oman, Portugal, Qatar, Syria, Spain, Switzerland, Tunisia, United Arab Emirates, UK and Yemen

To support the commercialization, Pharming will expand the current small European team of experienced HAE marketing and medical affairs specialists. To ensure a seamless hand-over and guarantee the continuous availability of Ruconest to patients, SOBI will continue to deliver Ruconest and continue the drug safety monitoring and reporting, until October 2016.